High pathologic complete response after primary chemotherapy in patients treated with weekly paclitaxel followed by FEC chemotherapy with simultaneous trastuzumab in Her-2 positive operable breast cancer

被引：0
|
作者：
Pernas, S.
Gil Gil, M.
Urruticoechea, A.
Fernandez-Ortega, A.
Falo, C.
Piulats, J. M.
Prieto, L.
Pla, M. J.
Moreno, A.
Germa, J. R.
机构：
[1] Hosp Barcelona, Inst Catala Oncol DIR, Barcelona, Spain
[2] Hosp Barcelona, HU Bellvitge, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：96 / 96
页数：1
相关论文
共 50 条
  • [1] Prospective data of additional patients treated with neoadjuvant therapy with paclitaxel followed by FEC chemotherapy with trastuzumab in HER-2 positive operable breast cancer, and an update of initial study population.
    Buzdar, AU
    Valero, V
    Ibrahim, N
    Francis, D
    Theriault, RL
    Green, M
    Hunt, K
    Sahin, A
    Buchholz, T
    Hortobagyi, GN
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S223 - S223
  • [2] Weekly paclitaxel and trastuzumab as first-line chemotherapy in patients with her-2 positive metastatic breast cancer
    Kim, Jin-Soo
    Han, Hye-Suk
    Im, Seock-Ah
    Oh, Do-Youn
    Han, Won-Shik
    Lee, Se-Hoon
    Kim, Dong-Wan
    Kim, Tae-You
    Noh, Dong-Young
    Bang, Yung-Jue
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 85 - 85
  • [3] Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Onoda, Naoyoshi
    Kashiwagi, Shinichiro
    Noda, Satoru
    Ishikawa, Tetsurou
    Wakasa, Kenichi
    Hirakawa, Kosei
    [J]. ONCOLOGY LETTERS, 2012, 4 (04) : 612 - 616
  • [4] High pathologic complete response rate effectively predicted by proliferation index in HER2-positive localized breast cancer tretated with weekly paclitaxel followed by FEC with concurrent trastuzumab
    Pernas, S.
    Urruticoechea, A.
    Falo, C.
    Pardo, B.
    Villanueva, R.
    Ortega, R.
    Garcia, A.
    Moreno, A.
    Perez, J.
    Gil, M.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S226 - S227
  • [5] Achieving high pathological complete response (pCR) rates in Her-2 positive patients with induction chemotherapy (ic) without trastuzumab in operable breast cancer.
    Abrial, C.
    Mouret-Reynier, M-A
    Penault-Llorca, F.
    Leheurteur, M.
    Durando, X.
    Raoelfils, I
    Achard, J-L
    Dauplat, J.
    Cure, H.
    Chollet, P.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S139 - S139
  • [6] High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin
    Chen, Shin-Cheh
    Chang, Hsien-Kun
    Lin, Yung-Chang
    Hsueh, Swei
    Cheung, Yun-Chung
    Leung, Wai-Man
    Tsai, Chien-Sheng
    Lo, Yung-Feng
    Tsai, Hsiu-Pei
    Shen, Shih-Che
    Chen, Miin-Fu
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (02) : 99 - 105
  • [7] Effect of Trastuzumab among HER2-Positive Breast Cancer Patients that Achieved Pathologic Complete Response after Neoadjuvant Chemotherapy
    Wang, Xinguang
    He, Yingjian
    Fan, Zhaoqing
    Wang, Tianfeng
    Xie, Yuntao
    Li, Jinfeng
    Ouyang, Tao
    [J]. BREAST CARE, 2019, 14 (06) : 388 - 393
  • [8] Complete response after docetaxel plus pertuzumab plus trastuzumab chemotherapy for multimetastatic positive Her-2 breast cancer
    Lai-Tiong, F.
    Van-Hulst, S.
    [J]. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (04) : 662 - 664
  • [9] Neoadjuvant therapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Her2 positive non operable breast cancer: a phase II study
    Levaggi, A.
    Poggio, F.
    Lambertini, M.
    D'Alonzo, A.
    Giraudi, S.
    Bighin, C.
    Blondeaux, E.
    Pastorino, S.
    Abate, A.
    Iacono, G.
    Vaglica, M.
    Conte, B.
    Pronzato, P.
    Del Mastro, L.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [10] High pathologic complete response in her-2-positive locally advanced breast cancer(LABC) after primary systemic chemotherapy with weekly docetaxel and epirubicin
    Chen, Shin-Cheh
    Lin, Yung-Chang
    Chang, Hsien-Kun
    Hsueh, Swei
    Leung, Wai-Man
    Tsai, Chien-Sheng
    Lo, Yung-Feng
    Tsai, Hsiu-Pei
    Shen, Shih-Che
    Chen, Miin-Fu
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 96 - 96
12345